SEC 8-K filings, classified by Claude with reasoning. Ingested in near-real time from EDGAR's filing stream, reconciled overnight.
Material 8-K events ordered by the time EDGAR accepted them. New filings appear at the top automatically — no refresh needed. Only filings ingested in near-real-time appear here; the daily-index reconciliation backstop fills in the catalog overnight, but those rows don't carry a sub-day timestamp and land on the Latest view instead.
This 8-K Item 5.07 discloses the results of Amprius Technologies' June 11, 2026 annual meeting of stockholders, including voting outcomes for two proposals: election of directors Kathleen Bayless and Thomas M. Stepien, and ratification of Deloitte & Touche LLP as independent auditor. The filing presents vote tallies (For, Against/Withheld, Abstentions, Broker Non-Votes) and confirms both proposals passed, which is the core disclosure required under Item 5.07.
iQSTEL amended and restated the Certificate of Designation for Series B Preferred Stock, materially relaxing conversion rights to permit conversion at any time with only 5 days' notice (versus previously only at the end of a 12-month term with 60 days' notice) and adding accrued dividend payouts upon conversion, affecting the Company's capital structure and dilution risk profile.
Kilroy Realty entered into a Fifth Amended and Restated Credit Agreement providing a $1.25 billion revolving credit facility (expandable to $1.7 billion) and an Amended and Restated Term Loan Agreement for a $250 million facility (expandable to $400 million) on June 12, 2026. These material refinancings and amendments to existing credit facilities affect the company's liquidity and financial flexibility but do not constitute a discrete M&A transaction, acquisition, disposition, or change of control.
The filing discloses Item 3.01 notification from Nasdaq that Vestand Inc. failed to regain compliance with the Minimum Bid Price Requirement (Rule 5550(a)(2)) during its 180-calendar-day compliance period ending June 10, 2026, and is ineligible for an additional compliance period. The company faces a Nasdaq Hearings Panel determination on continued listing, with suspension and delisting risk pending the outcome of its appeal. This is a material delisting risk event.
The Compensation Committee approved and adopted the Senior Executive Annual Bonus Plan on June 15, 2026, establishing a compensatory arrangement for executive officers and designated employees. The plan specifies performance metrics, payment mechanisms (cash or stock under the 2022 Equity Incentive Plan), and clawback provisions. This is a material disclosure of a new compensation plan affecting executive officers, fitting squarely within the exec_compensation category.
Dell disclosed the issuance of 3,438,364 shares of Class C common stock upon conversion of Class B common stock held by Silver Lake entities. While technically a conversion rather than a new issuance, this represents a dilutive equity event involving unregistered securities (relying on Section 3(a)(9) exemption) and a material change in the capital structure, with Class B shares declining from approximately 47.8M to 44.4M outstanding. The conversion by a significant shareholder (Silver Lake) is material to investors assessing ownership and control dynamics.
Ziff Davis completed the sale of its Connectivity division to Accenture Inc. for $1.2 billion in cash on June 17, 2026, following entry into the Securities Purchase Agreement on March 2, 2026 and lender consent on June 15, 2026.
AXT's subsidiary Tongmei entered into a long-term supply agreement with Casela committing Casela to purchase approximately $25.4 million of InP wafer substrates during 2027, with 50% prepayment required within 15 business days. While this is a material commercial contract (Item 1.01), it is fundamentally a supply/customer agreement rather than a merger, acquisition, disposition, or change of control. The agreement secures significant committed revenue and prepayment but does not fit the specific M&A taxonomy categories, warranting classification as other_material.
The company appointed Chris Hyder as Executive Vice President and Chief Operating Officer and Nina Barton as Executive Vice President and Chief Growth & Strategy Officer, both effective June 17, 2026. These material C-suite appointments include compensatory arrangements (salary increases and RSU grants) and reflect significant changes to the company's executive leadership structure.
This Item 5.07 disclosure reports the results of Aprea Therapeutics' 2026 annual meeting of stockholders held on June 16, 2026, including voting outcomes on six proposals: election of three Class I directors (Marc Duey, Richard Peters, M.D., and Bernd R. Seizinger, M.D., Ph.D.), ratification of EisnerAmper LLP as auditor, approval of a reverse stock split authorization (1-for-3 to 1-for-8 ratio), advisory votes on executive compensation and compensation vote frequency, and adjournment authority. The reverse stock split authorization is particularly material as it grants the Board discretion to implement a significant capital structure change that would affect all shareholders.
The filing discloses the appointment of Tyler Krutzig as Senior Vice President and Chief Accounting Officer effective September 1, 2026, following the announced retirement of Randolph A. Wacker. While both a departure and appointment occur, the principal disclosed action centers on the appointment of Krutzig to a key executive role (Chief Accounting Officer), making exec_appointment the most salient classification. The appointment is material as it involves a named executive officer in a critical financial reporting position.
This disclosure reports a seventh amendment to a business combination agreement (BCA) between Israel Acquisitions Corp and Gadfin Ltd., originally entered into on January 26, 2025 and amended multiple times through June 15, 2026. The amendment extends the termination date under Section 7.1(d) to June 20, 2026. This constitutes material M&A activity under Item 1.01, as it involves an ongoing material acquisition/business combination and modification of its key terms.
The Company entered into an underwriting agreement on June 15, 2026, to offer and sell 14,000,000 shares of common stock through a forward sale mechanism, with an additional 2,100,000 shares subject to an underwriter option. This is a material equity issuance that will dilute existing shareholders. Although structured as a forward sale (with settlement expected by June 16, 2027), the Company will receive net proceeds and contribute them to its operating partnership for acquisitions and general corporate purposes, making this a dilutive capital raise transaction.
The filing discloses Item 5.07 results from Hepion Pharmaceuticals' 2026 Annual Meeting of Stockholders held on June 17, 2026, including voting outcomes on three proposals: election of five directors (Gary Stetz, Vincent LoPriore, Michael Purcell, Sireesh Appajosyula, and Chase LoPriore), ratification of Grassi & Co. as independent auditors, and approval of an amendment to the 2023 Omnibus Equity Incentive Plan to increase authorized shares to 8,000,000. These shareholder votes are material to investors as they determine board composition and equity plan capacity.
Avalanche Treasury Corp completed a business combination with MLAC on June 11, 2026, following shareholder approval on June 4, 2026. The transaction involved entry into material definitive agreements (registration rights, indemnification, and lock-up agreements), significant shareholder redemptions of $243.2 million, and resulted in a change of control with a post-closing capitalization of 37.9 million Class A shares and 5.8 million Class B shares outstanding.
Three executive officers were appointed effective on the business combination closing date: Gerald Bartholomew Smith as CEO/President, Laine Mihalchick Moljo as COO/Secretary, and Sean Ostrower as CFO.
Pubco completed an unregistered private placement sale of equity securities to the Foundation under Section 4(a)(2) of the Securities Act in connection with the business combination.
The registrant adopted a First Amended and Restated Certificate of Incorporation and Bylaws in connection with the business combination closing, materially modifying the rights of Class A stockholders.
This is a clear disclosure of shareholder vote results from Neonode's 2026 Annual Meeting of Stockholders held on June 17, 2026, covering three proposals: election of directors (Peter Lindell and Per Löfgren), ratification of Crowe LLP as independent auditor, and an advisory say-on-pay vote. The filing presents voting tallies for each proposal, which is the quintessential content of Item 5.07 shareholder_vote_results disclosures.
Twilio held its Annual Meeting of stockholders on June 16, 2026, with voting results disclosed on June 17, 2026. Five proposals were voted on and approved by substantial majorities: election of four Class I directors, ratification of KPMG LLP as independent auditor, advisory vote on named executive officer compensation, and approval of amendments and restatements to the 2016 Stock Option and Incentive Plan and 2016 Employee Stock Purchase Plan.
JAB Acquisition Corp I disclosed the consummation of its initial public offering on June 11, 2026, raising $172.5 million in gross proceeds from 17.25 million units, plus a concurrent private placement of 260,000 units for $2.6 million. While technically an IPO/capital raise rather than a traditional M&A transaction, this represents a material capital event that establishes the company's public shell structure for a future business combination. The filing is disclosed under Item 8.01 (Other Events) and includes detailed terms of the securities issued, making it a material event affecting the registrant's capitalization and structure.
Brinker International issued a notice of redemption for all outstanding 8.250% Senior Notes due July 15, 2030, with redemption scheduled for July 15, 2026 at 104.125% of principal plus accrued interest. This is a material debt management event affecting the company's capital structure and liquidity, but does not fit neatly into the more specific taxonomy categories (not a covenant breach, not a restatement, not M&A activity). The redemption of a substantial debt obligation is material to investors assessing the registrant's financial position and cash flow.
QXO completed a $3.0 billion debt offering on June 17, 2026, explicitly designated as financing for the previously announced proposed acquisition of TopBuild Corp. The proceeds are held in escrow pending consummation of the acquisition, with a mandatory redemption trigger if the acquisition is not completed by January 31, 2027.
This is a clear restatement disclosure under Item 4.02. Management concluded on June 11, 2026 that previously issued condensed consolidated financial statements in two quarterly 10-Q filings should no longer be relied upon due to an error in the calculation of weighted-average shares outstanding used in EPS calculations. The error resulted in material overstatements and understatements of basic and diluted EPS across multiple periods (ranging from $0.08 to $4.26 per share), and the Company intends to file amended 10-Qs to restate the affected financial statements. This is a quintessential restatement event.
SeaStar Medical held its annual meeting of shareholders on June 17, 2026, with stockholders voting on four proposals: election of Class I director John Neuman, approval of an amended 2022 Omnibus Incentive Plan increasing authorized shares from 207,046 to 896,546, ratification of WithumSmith+Brown, PC as independent auditor, and adjournment authority. All four proposals passed.
Madrigal Pharmaceuticals held its Annual Meeting of Stockholders on June 17, 2026, with shareholders voting on five matters: re-election of three Class I directors, advisory vote on named executive officer compensation, ratification of PricewaterhouseCoopers LLP as independent auditor, approval of the 2026 Stock Plan, and approval of the 2026 Employee Stock Purchase Plan. The filing discloses complete voting tallies (For, Against, Abstentions, Broker Non-Votes) for each matter.
The Board adopted a Nonqualified Deferred Compensation Plan for named executive officers and directors, and entered into a consulting agreement with Dr. Rebecca Taub (Class II director) providing $100,000 annually plus director compensation. These compensatory arrangements were approved by stockholders as part of the Annual Meeting voting on the 2026 Stock Plan and 2026 Employee Stock Purchase Plan.
ImageneBio held its Annual Meeting on June 16, 2026, with shareholders voting on three proposals: election of two Class II directors (David P. Bonita and Joseph P. Slattery), ratification of PricewaterhouseCoopers LLP as independent auditor, and approval of the 2025 Amended Equity Incentive Plan.
Groupon held its 2026 Annual Meeting of Stockholders on June 11, 2026, with shareholders voting on four proposals: election of six directors, ratification of Deloitte & Touche LLP as independent auditor, advisory approval of named executive officer compensation, and approval of a certificate amendment for officer exculpation provisions.
This disclosure reports the completion of a disposition of a 100% equity interest in Bless HK (indirect owner of Jingshan subsidiary) to an unaffiliated third party on June 15, 2026. Although the consideration was nominal and the subsidiary was non-operating, the transaction constitutes a material change of control and elimination of a consolidated subsidiary from the Company's financial statements, which would affect a reasonable investor's assessment of the registrant's asset base and strategic direction.
This Item 5.07 filing discloses the results of Regeneron's 2026 Annual Meeting of Shareholders held on June 12, 2026, including voting outcomes for three proposals: election of Class II directors (five nominees), ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. The detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal are the core disclosure, which is the defining characteristic of shareholder_vote_results.
The filing discloses a proposed business combination between Nano Dimension Ltd. and Infinite Epigenetics, Inc., with a press release issued on June 16, 2026 providing additional information about the transaction. The disclosure references an anticipated Definitive Agreement, Form S-4 registration statement, and proxy statement/prospectus, all hallmarks of a material M&A transaction requiring shareholder approval. This is a material event that would significantly affect investor assessment of the registrant.
The filing discloses completion of a License Agreement with Arvinas and Pfizer granting Rigel exclusive global rights to develop, manufacture, and commercialize VEPPANU™ (vepdegestrant). The transaction involved a $70.0 million upfront payment and required HSR clearance, constituting a material acquisition of asset rights that would affect investor assessment of the company's product pipeline and financial position.
The filing discloses a material business combination agreement entered into on February 22, 2026, between RAAQ and IQM Quantum Computers Oy that will result in IQM becoming a publicly traded company. The June 17, 2026 8-K Item 8.01 announces the effectiveness of the Registration Statement (June 5, 2026) and the mailing of the definitive proxy statement/prospectus to shareholders for an upcoming Extraordinary General Meeting to vote on the Transaction. This is a material acquisition/change of control event that would substantially affect a reasonable investor's assessment of the registrant.
This Item 5.07 filing discloses the complete voting results from Zai Lab's 2026 Annual General Meeting of Shareholders held on June 17, 2026. The section presents detailed vote tallies for 14 proposals, including director re-elections (Proposals 1–9), auditor appointment (Proposal 10), auditor compensation authorization (Proposal 11), advisory vote on named executive officer compensation (Proposal 12), and general mandates for share issuance and repurchase (Proposals 13–14). All proposals were carried as ordinary resolutions. This is a textbook shareholder_vote_results disclosure required under Item 5.07 of Form 8-K.
Lesaka's subsidiary entered into a Transaction Implementation Agreement with Zero Research, Bank Zero, and multiple shareholders, indicating a material acquisition or merger transaction. The disclosure explicitly references Item 1.01 (Entry Into a Material Definitive Agreement), conditions precedent, and an extended closing deadline (January 31, 2027), all hallmarks of M&A activity. This would materially affect investor assessment of the registrant's strategic direction and financial position.
Faraday Future announced a major product launch on June 16, 2026, including unveiling its "full-form EAI Robot World spanning six product series," launching a "Three-in-One EAI robotics education ecosystem strategy," and debuting an "All-New Futurist humanoid robot and FX Navi with pricing starting at $1,990." This represents a significant business development and product diversification announcement that would materially affect investor assessment of the company's strategic direction and revenue prospects, but does not fit neatly into the more specific event categories (not an earnings release, M&A activity, impairment, or other defined event type).
Item 2.02 disclosure explicitly references a press release issued on June 17, 2026, and states that textual information from that press release is being furnished in connection with "Results of Operations and Financial Condition." This is the standard format for earnings release disclosures under Item 2.02, with the press release attached as Exhibit 99.1.
ISQ Open Infrastructure entered into a $60 million revolving credit facility (expandable to $180 million) on June 11, 2026, creating a direct financial obligation with customary covenants and events of default.
XCF Global terminated a $50 million equity purchase agreement with Helena Global Investment Opportunities I LTD. that had reserved approximately 55 million shares for potential issuance. While the termination itself eliminates dilution risk, the core event disclosed is the unwinding of a dilutive equity arrangement that previously posed material overhang and dilution concerns. The filing emphasizes the reduction in "potential dilution and associated market overhang," indicating this was a material equity issuance arrangement.
The 8-K discloses results of Biofrontera's Annual Meeting of Stockholders held on June 11, 2026, under Item 5.07. The filing reports three matters voted on: election of two Class II directors (Beth J. Hoffman, Ph.D. and Kevin D. Weber), approval of an amendment to the 2021 Omnibus Incentive Plan increasing authorized shares from 3.75M to 8.75M, and ratification of CBIZ CPAs P.C. as independent auditor. These are routine but material shareholder votes affecting governance and equity authorization.
The filing discloses a letter agreement with Stavros Vizirgianakis, the Chairman, in connection with his appointment as Executive Chairman. The material substance is the Board's approval of a 450,000 RSU grant under the 2023 Share Incentive Plan with a three-tranche vesting schedule. While the appointment itself is mentioned, the filing centers on the compensatory arrangement—the equity grant—which is the principal disclosed action and would materially affect investor assessment of executive compensation and dilution.
The filing discloses results of the Company's 2026 Annual Meeting of Shareholders held on June 11, 2026, with voting outcomes on four proposals: election of four directors, ratification of the independent auditor (CBIZ CPAs P.C.), advisory approval of named executive officer compensation, and approval of an amendment to the Equity Incentive Plan increasing authorized shares by 1,750,000. Item 5.07 explicitly presents detailed voting tallies for each proposal, which is the core disclosure required for shareholder vote results under the 8-K taxonomy.
Karen Hawkins, Chief Financial Officer and Secretary of Optex Systems Holdings, Inc., notified the Company on June 12, 2026 of her intention to resign effective December 31, 2026. The departure of a CFO is a material executive change that would affect a reasonable investor's assessment of the registrant's financial leadership and continuity. The filing explicitly states no disagreements or accounting issues were involved, confirming this is a straightforward departure disclosure.
This 8-K Item 5.07 discloses the certified results of Alector's 2026 annual meeting of stockholders held on June 17, 2026, including voting outcomes for three proposals: election of Class II directors (Elizabeth Garofalo, Errol De Souza, and Kristine Yaffe), ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents vote tallies (for, against, abstentions, broker non-votes) for each matter, which is the core disclosure required under Item 5.07 for shareholder meeting results.
Outset Medical entered into a material amendment to its purchasing agreement with HCA on June 14, 2026, committing HCA to purchase approximately $40 million in new Tablo Hemodialysis Systems from 2026 through 2028, representing a significant multi-year commercial commitment affecting the company's revenue pipeline.
The Board unanimously approved submitting governance proposals to stockholders to eliminate the classified board structure and all supermajority voting provisions in the Articles of Incorporation. This represents a material change to corporate governance structure that would affect shareholder voting rights and director election processes. While not fitting neatly into the specific event categories (it is not a shareholder vote result, but rather a proposal for one), the elimination of classified boards and supermajority voting provisions is material to investors' assessment of governance and control dynamics.
This is a clear Item 5.07 disclosure of shareholder vote results from AEON Biopharma's Annual Meeting of Stockholders held on June 17, 2026. The filing reports the final certified voting results for two proposals: (1) election of Class III directors Marc Forth and Seongsoo Park for three-year terms, and (2) ratification of KPMG LLP as independent auditor. Director elections and auditor ratifications are material governance matters affecting investor confidence in board composition and financial oversight.
Workhorse entered into Omnibus Amendment No. 2 on June 16, 2026, materially restructuring its credit facilities with MGMH by increasing the Cash Flow Credit Agreement commitment from $20M to $30M, deferring interest payments on the additional $10M tranche, reducing the Customer Order Credit Agreement from $30M to $20M, and obligating issuance of warrants as consideration. This material restructuring of debt facilities, commitment reallocation, and dilutive warrant issuance constitute a material change in the Company's capital structure and financial obligations.
This Item 5.07 disclosure reports the results of Mastercard's June 16, 2026 annual meeting of stockholders, including votes on director elections (11 nominees), advisory approval of executive compensation, ratification of PricewaterhouseCoopers LLP as auditor, and two shareholder proposals. The detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each matter are the core content, making this a textbook shareholder_vote_results event that is material to investors assessing board composition and governance outcomes.